Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Despite the physical and mental battles, and constant medical appointments, Sandor, 44, and Erika, 54, say they are ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Some risk factors for epithelial ovarian cancer are modifiable, according to a study published online Jan. 6 in the ...

High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a ...

High-grade serous ovarian cancer (HGSC) is among the most lethal gynecologic malignancies, with up to 90% of patients eventually becoming resistant to platinum-based chemotherapy. The limited ...

Their work is published in the journal npj Genomic Medicine. High-grade serous ovarian cancer (HGSOC) is the most common type of epithelial ovarian cancer and is often diagnosed at an advanced ...

Olaparib, a PARP inhibitor, shows promise as a maintenance therapy for patients with newly diagnosed advanced-stage, high-grade serous ovarian cancer who are HRD-positive but BRCA wild-type.

Ovarian cancer continues to pose a significant challenge in the medical field, remaining one of the leading causes of death ...